Bausch Health (NYSE: BHC) director sells 24,456 shares under plan
Rhea-AI Filing Summary
Bausch Health Companies Inc. director Frank D. Lee reported an open-market sale of common shares. On May 19, 2026, he sold 24,456 common shares at an average price of $5.43 per share. Following this transaction, he directly holds 49,339 common shares.
According to the footnote, the shares were sold in the open market under a Rule 10b5-1 trading plan to fund estimated tax obligations from a previously vested equity award granted to the company’s non-employee directors. The filing shows no derivative positions remaining in this report.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 24,456 shares
Net Sell
1 txn
Insider
Lee Frank D.
Role
Director
Sold
24,456 shs ($133K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Shares, No Par Value | 24,456 | $5.43 | $133K |
Holdings After Transaction:
Common Shares, No Par Value — 49,339 shares (Direct)
Footnotes (1)
- F1. Represents shares of the Issuer's common stock, no par value, sold in the open market pursuant to a Rule 10b5-1 trading plan to fund estimated tax obligations arising from a previously vested equity award granted to the Issuer's non-employee directors.
Key Figures
Shares sold: 24,456 shares
Sale price per share: $5.43 per share
Shares held after transaction: 49,339 shares
+1 more
4 metrics
Shares sold
24,456 shares
Open-market sale of common shares on May 19, 2026
Sale price per share
$5.43 per share
Average price for the 24,456 common shares sold
Shares held after transaction
49,339 shares
Direct common share holdings following the reported sale
Net shares sold
24,456 shares
Net sell direction from transaction summary
Key Terms
Rule 10b5-1 trading plan, previously vested equity award, non-employee directors, Common Shares, No Par Value
4 terms
Rule 10b5-1 trading plan regulatory
"sold in the open market pursuant to a Rule 10b5-1 trading plan to fund estimated tax obligations"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
previously vested equity award financial
"tax obligations arising from a previously vested equity award granted to the Issuer's non-employee directors"
non-employee directors financial
"previously vested equity award granted to the Issuer's non-employee directors"
Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Bausch Health (BHC) report for director Frank D. Lee?
Bausch Health reported that director Frank D. Lee sold 24,456 common shares in an open-market transaction at an average price of $5.43 per share. This Form 4 filing reflects a single sale of non-derivative common shares on May 19, 2026.
Was the Bausch Health (BHC) insider sale by Frank D. Lee part of a Rule 10b5-1 plan?
Yes. The filing explains that the common shares were sold in the open market pursuant to a Rule 10b5-1 trading plan. Such plans are pre-arranged trading programs designed to allow insiders to sell shares on a predetermined schedule.
Did the Bausch Health Form 4 involve derivative securities for Frank D. Lee?
No. The disclosed transaction involves non-derivative common shares with no associated options or other derivatives exercised or converted. The derivative summary section in the data is empty, indicating no derivative transactions were reported in this Form 4.